{"entity":{"id":"gabapentin","kind":"drug","name":"Gabapentin","aka":[],"tldr":"Gabapentin is a tablet for nerve pain and epilepsy. In cancer care it is used for nerve pain caused by the cancer or its treatment, and sometimes for hot flushes.","summary":"The Neurontin label covers postherpetic neuralgia and adjunctive treatment of partial-onset seizures. The Japan Society of Pain Clinicians (2025) weakly recommends gabapentinoids for neuropathic pain directly related to cancer in survivors because they can reduce the opioid dose needed [2B]. SITC 2021 says people with painful peripheral neuropathy from checkpoint inhibitors \"should receive neuropathic pain medication such as gabapentin, pregabalin, or duloxetine until neuropathy resolves\". Cancer Care Ontario lists gabapentin among non-hormonal options for hot flushes in women and men with cancer. The NDA was first approved on 30 December 1993.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Gabapentin","links":[{"label":"US label (DailyMed): Neurontin","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97935fd9-1d4a-43b6-a5d9-de994591187b"},{"label":"Japan Society of Pain Clinicians, Consensus statement on chronic pain treatment in cancer survivors (J Anesth 2025)","url":"https://doi.org/10.1007/s00540-024-03427-0"},{"label":"Brahmer et al., SITC clinical practice guideline on immune checkpoint inhibitor-related adverse events (J Immunother Cancer 2021)","url":"https://doi.org/10.1136/jitc-2021-002435"},{"label":"Barbera et al., Interventions to address sexual problems in people with cancer (Cancer Care Ontario guideline, Curr Oncol 2017), vasomotor symptoms","url":"https://doi.org/10.3747/co.24.3583"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["duloxetine","venlafaxine"],"cancers":[],"sections":[],"technologies":["pain-management"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["peripheral-neuropathy","hot-flushes-on-hormone-therapy","irae"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Neurontin","modality":"Gabapentinoid (oral)","supportive":true,"mechanism":"Binds the alpha-2-delta subunit of voltage-activated calcium channels; the label states that the precise mechanism of its analgesic and antiepileptic actions is unknown.","approvals":[{"region":"US","year":1993,"indication":"Postherpetic neuralgia; adjunctive treatment of partial-onset seizures","note":"Year is the Neurontin NDA 020235 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/gabapentin/","neighbours":{"drug":[{"id":"cyproterone","kind":"drug","name":"Cyproterone acetate","route":"/drugs/cyproterone/"},{"id":"duloxetine","kind":"drug","name":"Duloxetine","route":"/drugs/duloxetine/"},{"id":"venlafaxine","kind":"drug","name":"Venlafaxine","route":"/drugs/venlafaxine/"}],"technology":[{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/"}],"term":[{"id":"hot-flushes-on-hormone-therapy","kind":"term","name":"Hot flushes on hormone therapy","route":"/terms/hot-flushes-on-hormone-therapy/"},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/"},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/"}]}}